vs
Side-by-side financial comparison of InMed Pharmaceuticals Inc. (INM) and INTRUSION INC (INTZ). Click either name above to swap in a different company.
INTRUSION INC is the larger business by last-quarter revenue ($1.5M vs $820.2K, roughly 1.8× InMed Pharmaceuticals Inc.). INTRUSION INC runs the higher net margin — -190.7% vs -247.3%, a 56.5% gap on every dollar of revenue. On growth, INTRUSION INC posted the faster year-over-year revenue change (-11.6% vs -26.2%). Over the past eight quarters, INTRUSION INC's revenue compounded faster (14.4% CAGR vs -16.4%).
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
INTRUSION INCINTZEarnings & Financial Report
Intrusion Inc. is a cybersecurity company based in Plano, Texas. It provides cybersecurity solutions, including network intrusion detection and prevention systems.
INM vs INTZ — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $820.2K | $1.5M |
| Net Profit | $-2.0M | $-2.8M |
| Gross Margin | 22.5% | 74.3% |
| Operating Margin | -247.3% | -192.4% |
| Net Margin | -247.3% | -190.7% |
| Revenue YoY | -26.2% | -11.6% |
| Net Profit YoY | 21.2% | -44.4% |
| EPS (diluted) | $-0.51 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $820.2K | $1.5M | ||
| Q3 25 | $1.1M | $2.0M | ||
| Q2 25 | $1.3M | $1.9M | ||
| Q1 25 | $1.3M | $1.8M | ||
| Q4 24 | $1.1M | $1.7M | ||
| Q3 24 | $1.3M | $1.5M | ||
| Q2 24 | $1.3M | $1.5M | ||
| Q1 24 | $1.2M | $1.1M |
| Q4 25 | $-2.0M | $-2.8M | ||
| Q3 25 | $-1.7M | $-2.1M | ||
| Q2 25 | $-1.8M | $-2.0M | ||
| Q1 25 | $-2.1M | $-2.1M | ||
| Q4 24 | $-2.6M | $-2.0M | ||
| Q3 24 | $-1.7M | $-2.0M | ||
| Q2 24 | $-1.9M | $-2.1M | ||
| Q1 24 | $-1.7M | $-1.7M |
| Q4 25 | 22.5% | 74.3% | ||
| Q3 25 | 36.0% | 76.6% | ||
| Q2 25 | 44.2% | 76.4% | ||
| Q1 25 | 13.9% | 75.7% | ||
| Q4 24 | 41.5% | 74.9% | ||
| Q3 24 | 39.0% | 77.1% | ||
| Q2 24 | 36.3% | 76.0% | ||
| Q1 24 | 24.7% | 80.0% |
| Q4 25 | -247.3% | -192.4% | ||
| Q3 25 | -154.2% | -108.6% | ||
| Q2 25 | -137.1% | -111.4% | ||
| Q1 25 | -168.1% | -117.9% | ||
| Q4 24 | -231.6% | -113.5% | ||
| Q3 24 | -132.7% | -135.5% | ||
| Q2 24 | -150.5% | -139.2% | ||
| Q1 24 | -146.9% | -218.6% |
| Q4 25 | -247.3% | -190.7% | ||
| Q3 25 | -154.2% | -106.5% | ||
| Q2 25 | -137.1% | -109.0% | ||
| Q1 25 | -168.1% | -118.2% | ||
| Q4 24 | -231.6% | -116.8% | ||
| Q3 24 | -132.7% | -136.3% | ||
| Q2 24 | -151.0% | -141.6% | ||
| Q1 24 | -146.9% | -151.7% |
| Q4 25 | $-0.51 | $-0.15 | ||
| Q3 25 | $-0.44 | $-0.10 | ||
| Q2 25 | $-0.07 | $-0.10 | ||
| Q1 25 | $-1.94 | $-0.11 | ||
| Q4 24 | $-3.64 | $0.19 | ||
| Q3 24 | $-2.71 | $-0.35 | ||
| Q2 24 | $2.39 | $-0.53 | ||
| Q1 24 | $-3.58 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.0M | $3.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.6M | $7.3M |
| Total Assets | $11.2M | $10.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.0M | $3.6M | ||
| Q3 25 | $9.4M | $4.5M | ||
| Q2 25 | $11.1M | $8.4M | ||
| Q1 25 | $4.7M | $10.7M | ||
| Q4 24 | $3.5M | $4.9M | ||
| Q3 24 | $5.6M | $1.1M | ||
| Q2 24 | $6.6M | $1.5M | ||
| Q1 24 | — | $122.0K |
| Q4 25 | $9.6M | $7.3M | ||
| Q3 25 | $11.6M | $9.8M | ||
| Q2 25 | $13.4M | $11.6M | ||
| Q1 25 | $7.0M | $13.4M | ||
| Q4 24 | $6.2M | $6.3M | ||
| Q3 24 | $8.4M | $2.6M | ||
| Q2 24 | $9.2M | $2.9M | ||
| Q1 24 | $11.1M | $-1.2M |
| Q4 25 | $11.2M | $10.4M | ||
| Q3 25 | $13.4M | $13.7M | ||
| Q2 25 | $15.6M | $16.4M | ||
| Q1 25 | $9.3M | $18.0M | ||
| Q4 24 | $8.5M | $11.5M | ||
| Q3 24 | $10.5M | $7.4M | ||
| Q2 24 | $11.8M | $7.5M | ||
| Q1 24 | — | $5.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.4M | $-531.0K |
| Free Cash FlowOCF − Capex | — | $-549.0K |
| FCF MarginFCF / Revenue | — | -37.1% |
| Capex IntensityCapex / Revenue | — | 1.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-7.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.4M | $-531.0K | ||
| Q3 25 | $-1.6M | $-3.0M | ||
| Q2 25 | $-1.8M | $-1.6M | ||
| Q1 25 | $-1.7M | $-1.7M | ||
| Q4 24 | $-2.5M | $-178.0K | ||
| Q3 24 | $-1.8M | $-2.1M | ||
| Q2 24 | $-1.0M | $-2.9M | ||
| Q1 24 | $-1.9M | $-1.1M |
| Q4 25 | — | $-549.0K | ||
| Q3 25 | — | $-3.0M | ||
| Q2 25 | — | $-1.9M | ||
| Q1 25 | — | $-2.1M | ||
| Q4 24 | — | $-645.0K | ||
| Q3 24 | — | $-2.1M | ||
| Q2 24 | — | $-3.0M | ||
| Q1 24 | $-1.9M | $-1.2M |
| Q4 25 | — | -37.1% | ||
| Q3 25 | — | -153.2% | ||
| Q2 25 | — | -101.1% | ||
| Q1 25 | — | -117.3% | ||
| Q4 24 | — | -38.5% | ||
| Q3 24 | — | -140.4% | ||
| Q2 24 | — | -202.3% | ||
| Q1 24 | -165.0% | -104.2% |
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 17.8% | ||
| Q1 25 | — | 22.1% | ||
| Q4 24 | — | 27.9% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | 0.0% | 5.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
